About
Technology
Issues
FAQ
Links
Official Page
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.